Regulation of PTEN by C-tail Phosphorylation 1 Molecular Features of PTEN Regulation by C-Terminal Phosphorylation
Zan Chen,Daniel R. Dempsey,Stefani N. Thomas,Dawn Hayward,David M. Bolduc,Philip A. Cole
2016-01-01
Abstract:PTEN is a tumor suppressor that functions to negatively regulate the PI3K/AKT pathway as the lipid phosphatase for phosphatidyl inositol 3,4,5-triphosphatse (PIP3). Phosphorylation of a cluster of Ser/Thr residues (aa 380-385) on the Cterminal tail serves to alter the conformational state of PTEN from an open active state to a closed inhibited state, resulting in a reduction of plasma membrane localization and inhibition of enzyme activity. The relative contribution of each phosphorylation site to PTEN autoinhibition and the structural basis for the conformational closure is still unclear. To further the structural understanding of PTEN regulation by C-terminal tail phosphorylation, we used protein semisynthesis to insert stoichiometric and sitespecific phospho-Ser/Thr(s) in the C-terminal tail of PTEN. Additionally, we employed photocrosslinking to map the intramolecular PTEN interactions of the phospho-tail. Systematic evaluation of the PTEN C-tail phospho-cluster showed autoinhibition and conformational closure was influenced by the aggregate effect of multiple phospho-sites rather than dominated by a single phosphorylation site. Moreover, photocrosslinking suggested a direct interaction between the PTEN C-tail and a segment in the N-terminal region of the catalytic domain. Mutagenesis experiments provided additional insights into how the PTEN phospho-tail interacts with both the C2 and catalytic domains. PTEN is a phosphatidyl 3,4,5-triphosphate (PIP3) lipid phosphatase that is frequently inactivated in cancer by mutation, epigenetic silencing, or post-translational modifications (PTMs) (1-8). Loss of PTEN function allows unabated production of PIP3 from PIP2 by PI3kinases and stimulates the AKT protein kinase signaling pathway and cancer cell proliferation (1,9,10). Understanding the mechanisms of PTEN regulation is therefore critical to the development of therapeutics that can treat a wide variety of cancers. PTEN is a ~45 kDa protein composed of an N-terminal PTP-type phosphatase domain, a mid-section phospholipid membrane interacting C2 domain and a 50 residue regulatory tail (1). A crystal structure of the core PTEN catalytic-C2 region has revealed intimate interactions between the catalytic and C2 domains but omitted the Cterminal tail, which is considered to be flexible and largely unstructured (11). One of the most intensively studied set of PTMs in PTEN is a cluster of four C-terminal phosphorylations at Ser380, Thr382, Thr383, and Ser385 (12-15). These phosphorylation events have been suggested to be catalyzed by protein kinases CK2 and/or GSK3ß and demonstrated to drive a http://www.jbc.org/cgi/doi/10.1074/jbc.M116.728980 The latest version is at JBC Papers in Press. Published on May 11, 2016 as Manuscript M116.728980 Copyright 2016 by The American Society for Biochemistry and Molecular Biology, Inc. by gest on M ay 7, 2016 hp://w w w .jb.org/ D ow nladed from Regulation of PTEN by C-tail Phosphorylation 2 conformational change that inhibits membrane interactions and reduces catalytic activity (12-15). Several reports that shed light on the molecular basis for this phospho-dependent regulatory event suggest that the PTEN tailphosphorylation induces conformational closure involving intramolecular interactions between the tail and the CBR3 loop of PTEN's C2 domain (1416). However, important aspects of this structural model remain undetermined. It is not known whether all four tail phosphorylation events are necessary for PTEN’s conformational closure or whether specific individual sites are critical for this tertiary structural change. Recently, a mutant form of PTEN, ePTEN, was identified through a genetic screen as a form of PTEN that constitutively binds the membrane, despite Cterminal phosphorylation (17). The five mutations in ePTEN, Q17R, R41G, E73D, N262Y, and N329H, are widely spaced throughout the PTEN domains (17). It was hypothesized, but not investigated in detail, that these mutations disrupt the phosphorylation-driven conformational change in PTEN (17). Other studies on PTEN including H/D exchange experiments have suggested that the catalytic domain and/or the N-terminus may also interact with the phosphorylated tail (18). To help clarify these phospho-PTEN structural issues, we have applied expressed protein ligation (19) to generate several semisynthetic phosphorylated forms of PTEN, and we assessed their activity and tail interactions. We demonstrated that there is an approximately proportional relationship between the number of phosphates and degree of conformational closure. In contrast to expectations, tetraphosphorylated ePTEN (4p-ePTEN) showed a closed conformation similar to that of wt 4p-PTEN. However, mutations of a cluster of Lys and Arg residues in the Cα2 loop relaxed phospho-tail interactions with the PTEN body. The incorporation of a benzolyphenylalanine in the Ctail was employed in photocrosslinking experiments and provided direct evidence for a tail-catalytic domain interaction. Here, we describe how this biochemical analysis of a new set of semisynthetic PTENs has led to significant insights into the structural basis for the effects of PTEN tail phosphorylation. Experimental Procedures Reagents Soluble diC6-PIP3 was purchased from Avanti Polar Lipids (Alabaster, AL). Antiphospho-PTEN antibody was from abcam (ab131107), and anti-total PTEN antibody was from Santa Cruz (sc-7974). Calf intestinal alkaline phosphatase (CIP) was purchased from New England Biolabs (M0290). MESNA was supplied from Sigma (St. Louis, MO). All canonical Fmoc-amino acids were from EMD (Billerica, MA), whereas Fmoc-L-pbenzoylphenylalanine and Fmoc-L-Lys(biotin)Wang resin were purchased from Novabiochem and Iris Biotech, respectively. All other reagents were of the highest quality and were purchased from either Sigma or Fisher. Peptide synthesis Peptides were synthesized using the PS3 peptide synthesizer or the Prelude X peptide synthesizer from Protein Technologies (Tuscon, AZ) using conventional Fmoc solid phase peptide synthesis strategies. Synthetic peptides were estimated to be greater than 90% pure after HPLC and their correct structures were confirmed by matrix-assisted laser desorption ionization (MALDI) mass spectrometry. Peptide samples were spotted using the sandwich method with α-cyano-4-hydroxycinnamic acid as the matrix (10 mg/mL CHCA in 50% acetonitrile, 5 mM ammonium citrate). Mass spectra were acquired using the Voyager-DE STR BioSpectrometry Workstation (Applied Biosystems) by averaging 100 shots using a linear detector in either positive (unphosphorylated peptides) or negative ion (phosphorylated peptides) mode. Generation and purification of semisynthetic PTEN Expressed protein ligation was used to generate different semisynthetic phosphorylated PTENs as previously reported by Bolduc et al (14). In brief, a C-terminal truncated PTEN (tPTEN: aa1-378) fused to Mycobacterium xenopi GyrA intein and chitin-binding domain (tPTEN-inteinCBD) was subcloned into the pFastBac-1 vector and transformed into DH10Bac competent cells, in order to produce a bacmid containing the appropriate PTEN sequence. Site-directed mutants were generated by standard quikchange methods using the primers shown in Table 1. The bacmid containing t-PTEN-intein-CBD was then transfected into Sf-21 insect cells to generate the by gest on M ay 7, 2016 hp://w w w .jb.org/ D ow nladed from Regulation of PTEN by C-tail Phosphorylation 3 corresponding baculovirus needed for protein expression. High Five insect cells were infected with the baculovirus at a cell density of 1 million/mL and cultured for 48 h at 27°C to express tPTEN-intein-CBD. The final culture was then harvested by centrifugation and the cell pellet lysed with a Dounce homogenizer by 40 strokes in 40 mL of 50 mM HEPES pH 7.5, 250 mM NaCl, 1 mM EDTA, 10% glycerol, and one tablet of complete EDTA-free protease inhibitor cocktail (Roche Diagnostics). The soluble lysate was then incubated with fibrous cellulose (Sigma) for 30 min at 4°C to remove chitinase. Next, t-PTENintein-CBD was immobilized by passing it over chitin resin, followed by rigorous washing with 25 mM HEPES pH 7.5, 250 mM NaCl, 1 mM EDTA, 0.1% Triton and 50 mM HEPES pH 7.5, 250 mM NaCl, 1 mM EDTA. Semisynthetic PTEN was then generated by incubating the t-PTEN-inteinCBD-bound chitin resin for 48 – 72 h at room temperature with 50 mM HEPES pH 7.2, 250 mM NaCl, 400 mM MESNA, and 2 mM of the corresponding C-terminal tail peptide. Truncated PTENs were generated by incubating the chitin resin with 50 mM HEPES pH 7.2, 250 mM NaCl, 400 mM MESNA, and 40 mM cysteine for 24 h at room temperature. Following the ligation reaction, semisynthetic PTEN was eluted from the chitin resin in 50 mM Tris pH 8.0, 5 mM NaCl, 5 mM DTT, followed by dialysis with the same buffer to remove unreacted peptide and salt from the ligation reaction. The semisynthetic PTEN was then further purified by FPLC-anion exchange chromatography (MonoQ, GE Healthcare) using a 240 mL linear gradient (0% to 50% Buffer B), whereby Buffer A is the dialysis buffer and Buffer B is 50 mM Tris pH 8.0, 1 M NaCl, 5 mM DTT. Enzyme activity assay Lipid phosphatase activity of PTEN towards the aqueous soluble substrate diC6-PIP3 was measured by monitoring phosphate release using the Malachite Green assay kit (R&D Biosystems) at 620 nm. Initial velocities were measured for a 25 μL reaction containing 50 mM Tris pH 8.0, 10 mM BME, 0.05 mg/mL ovalbumin, and varying concentrations of diC6-PIP3 (20–160 μM). Reactions were initiated with 0.5–20 μg of the corresponding PTEN and reaction rates were measured for 5–10 minutes at 30°C. Reactions were then quenched and inorganic phosphate measured using the Malachite Green assay kit. Background corrections were performed with quenched enzyme. All measurements were performed in duplicate on at least two separate occasions and replicates typically agreed within 20%. The kcat/Km measurements derived from this